Skip to main content

Table 1 Result of tissue DNA analysis by TEMPUS (TEMPUS biotechnology, Chicago, IL) showing potentially actionable mutations and variants of unknown significance

From: Exceptional response to chemotherapy followed by concurrent radiotherapy and immunotherapy in a male with primary retroperitoneal serous Adenocarcinoma: a case report and literature review

Somatic variants with potentially actionable mutations

Mechanism

Allelic fraction (%)

Mutation effect

TPF3

Point Mutation

47.91

p.G245D

NF1

Point Mutation

46.44

p.Q209

Variants of unknown significance (VUS)

 NCOR2

Point Mutation

30.42

p.D1708G

 CARD10

Point Mutation

27.17

p.R424W

 FUS

Splice Site

7.05

c.1542-7_1

542-5delTTT

 ADAMTS20

Point Mutation

3.59

p.Y948fs

 BRPF3

Point Mutation

3.37

p.P854fs

 EPHA3

Point Mutation

29.94

p.L588 V

Back to article page